Jeremiah Pharms Jr.

Career StatsC-

Year	Team	GP	Sacks	Tkl	TFL
Career		31	2.0	45	6.5
2025		3	0.0	3	1
2024		16	2.0	33	5
2023		12

Current Contract

Contract Value Index (CVI)

Net of age, position, and term, Jeremiah Pharms Jr.'s deal earns a C Contract Value Index. At $1.005M AAV on a one-year deal, the contract itself carries minimal financial risk—he's occupying a depth slot at a position where replacement-level options are plentiful and cheap. His 2025 season production of 3 tackles across 3 games underscores his current standing as emergency roster filler rather than a contributor with upside; paired with his C- performance grade, there's little on-field justification for expecting meaningful impact. As a 29-year-old fourth-year player, Pharms is solidly in the veteran depth phase of his career, and the Patriots' recent signings of Travis Shaw at defensive tackle and their acquisition of high-impact talent at receiver and tackle suggest the organization views him as organizational ballast rather than part of the competitive core. The Contract Value Index reflects exactly what the mediaframing describes: a routine practice squad shuffle that maintains positional depth without representing any meaningful capital allocation or long-term bet on his trajectory. For a one-year, sub-$1.1M deal, there's no downside exposure—this is the kind of low-risk, low-reward transaction that defines NFL roster churn during the preseason and injury seasons.

Contracts in the Same Value Band

Other same-position deals the Contract Value Index also places in the C band — a quick read on where Jeremiah's contract sits relative to comparable money.

Performance Analysis

Jeremiah Pharms Jr. is a three-year veteran defensive tackle for the New England Patriots currently grading out at C-minus. At 29 years old with 31 career games under his belt, Pharms represents a mid-rotation interior defender who has shown modest production but faces questions about consistency and ceiling. His developmental arc has been inconsistent, ranging from an F-grade season in 2023 to a D-plus performance this year, signaling a player still searching for reliable impact. Pharms' current-season tackle production stands at 2.06 per game, slightly above the NFL average of 1.82 and demonstrating solid gap assignment and run-stuffing instincts. His tackle-for-loss rate of 0.31 per game edges past the league average of 0.27, indicating above-average ability to disrupt ball carriers in the backfield. However, his pass-rush metrics reveal a notable weakness: 0.13 sacks per game falls just shy of the NFL average of 0.14, while his 0.31 QB hits per game barely tracks the league standard of 0.29—numbers that underscore his limitations as a pressure generator on obvious passing downs. Pharms' trajectory suggests a player whose best football may still be ahead, though the recent D-plus grade offers tempered optimism. To justify long-term roster investment, he must demonstrate more consistent production against elite competition and develop tangible pass-rush counters. Watch whether increased snap count opportunities in 2025 yield efficiency gains or reveal fundamental limitations in his ceiling as an NFL defender.

How Jeremiah Compares at the Position

Jeremiah Pharms Jr. ranks 110th of 217 graded defensive tackles by performance. That slots Jeremiah between Anthony Campbell (C) just ahead and Naquan Jones (C-) just behind.

Fan Sentiment

Patriots add depth with a practice squad elevation that signals roster tinkering rather than impact. Multiple headlines confirm Pharms Jr. cleared waivers and rejoined the practice squad before elevation. The move suggests New England needs interior defensive line depth but lacks star power. Fans view this as a routine roster move with minimal playoff implications for the team. Expect Pharms Jr. to operate as a rotational backup unless injuries create opportunity.